Pfizer/Ligand's Lasofoxifene Is First "Next-Generation" SERM Filed At FDA

NDA for the selective estrogen receptor modulator has an estimated user fee date of June 2005 for post-menopausal osteoporosis prevention indication. Drug could offer benefits over Lilly's SERM Evista, Ligand says.